A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Naïve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin
Phase of Trial: Phase III
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Daclatasvir (Primary) ; Peginterferon lambda-1a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms MAGNITUDE
- Sponsors Bristol-Myers Squibb
- 16 Mar 2015 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov record.
- 30 Oct 2014 Planned End Date changed from 1 Aug 2015 to 1 Jan 2015 as reported by Clinicaltrials.gov.
- 30 Oct 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Jan 2015 as reported by Clinicaltrials.gov